StevenMHorwitzMD

PubMed

• Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in T- and/or NK-cell lymphoma patients.
  Rohan Sardana, David Nemirovsky, Denise Frosina, Achim Jungbluth, Maria E Arcila, Andriy Derkach, Ying Liu, William T Johnson, Santosha A Vardhana, Steven M Horwitz, A...> ;Blood Advances. 2024 Apr 9
• Failing Forward in Peripheral T-Cell Lymphoma.
  Neha Mehta-Shah, Steven M Horwitz> ;Journal of Clinical Oncology. 2024 Mar 26
• BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cel...
  Robert Stuver, Agrima Mian, Samantha Brown, Sean Devlin, Paolo F Caimi, Stephanie Chinapen, Parastoo Dahi, Robert Dean, Zachary D Epstein-Peterson, Brian Hill, Steven ...> ;American Journal of Hematology. 2024 Mar 25
• Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.
  Krystel-Whittemore, M., Petrova-Drus, K., Ptashkin, R., Ewalt, M., Yao, J., Liu, Y., Zhu, M., Benhamida, J., Durham, B., Kumar, J., Nafa, K., Kiecka, I., Bowman, A., G...> ;Haematologica. 2024 Mar 7
• Breast Implant Associated Anaplastic Large Cell Lymphoma: Evidence-Based Consensus Conference Statement From The American Association of Plastic Surgeons.
  Clemens, M., Di Napoli, A., Jaffe, E., Haymaker, C., Hunt, K., McCarthy, C., Miranda, R., Prince, H., Santanelli di Pompeo, F., Holmes, S., Phillips, L., Myckatyn, T.,...> ;Plastic and Reconstructive Surgery. 2024 Feb 27
• ASO Author Reflections: Approaching BIA-ACL Diagnosis and Treatment.
  Kim, M., Vorstenbosch, J., Ghione, P., Plitas, G., Horwitz, S., Cordeiro, P., Nelson, J., McCarthy, C.> ;Annals of Surgical Oncology. 2024 Apr 1
• Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs).
  Alison J Moskowitz, Robert N Stuver, Steven M Horwitz> ;Blood. 2024 Feb 2
• Role of flow cytometric immunophenotyping in the diagnosis of breast implant-associated anaplastic large cell lymphoma: A 6-year, single-institution experience.
  Alexander Chan, Romany Auclair, Qi Gao, Paola Ghione, Steven Horwitz, Ahmet Dogan, Mikhail Roshal, Oscar Lin> ;Cytometry. Part B, Clinical Cytometry. 2024 Mar 1
• Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP.
  Bantilan, K., Smith, A., Maurer, M., Teruya-Feldstein, J., Matasar, M., Moskowitz, A., Straus, D., Noy, A., Palomba, M., Horwitz, S., Hamlin, P., Portlock, C., Cerhan,...> ;Blood Advances. 2024 Jan 25
• ASO Visual Abstract: Surgical Management and Long-Term Outcomes of BIA-ALCL: A Multidisciplinary Approach.
  Vorstenbosch, J., Kim, M., Ghione, P., Plitas, G., Horwitz, S., Cordeiro, P., Nelson, J., McCarthy, C.> ;Annals of Surgical Oncology. 2024 Mar 1
• Surgical Management and Long-Term Outcomes of BIA-ALCL: A Multidisciplinary Approach.
  Vorstenbosch, J., Kim, M., Ghione, P., Plitas, G., Horwitz, S., Cordeiro, P., Nelson, J., McCarthy, C.> ;Annals of Surgical Oncology. 2024 Mar 1
• 2 citations
  Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.
  Robert Stuver, Zachary D Epstein-Peterson, Steven M Horwitz> ;Haematologica. 2023 Dec 1
• 1 citations
  TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
  Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla B Heavican-Foral, Elisa Mandato, Huiyun Liu, Geoffrey M Nelson, Lu Yang, Renee Chen, Katherine...> ;Science Translational Medicine. 2023 Sep 20
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 3 citations
  TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
  William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan...> ;Blood Advances. 2023 Sep 12
• Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
  Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M Lia Palomba, Ali...> ;Haematologica. 2024 Jan 1
• Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions.
  Robert Stuver, Steven M Horwitz, Zachary D Epstein-Peterson> ;Current Treatment Options in Oncology. 2023 Aug 1
• 3 citations
  Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
  Robert Stuver, Steven M Horwitz, Ranjana H Advani, Julie M Vose, Hun Ju Lee, Neha Mehta-Shah, Jasmine M Zain, Bradley Haverkos, Mary Jo Lechowicz, Alison J Moskowitz, ...> ;British Journal of Haematology. 2023 Aug 1
• The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
  Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H Advani, Stefano A Pileri, Martina Manni, Steven M Horwitz, Francine M Fo...> ;Blood Advances. 2023 Sep 12
• Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
  Michael J Buege, Esther Drill, Steven M Horwitz, Andréa LeVoir, Terry Pak, Tim J Peterson, Phuong H Dao, Matthew J Matasar> ;European Journal of Haematology. 2023 Jul 1
• 2 citations
  Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
  Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A Hamlin, Steven Horwitz, Anita Kumar, Matthew J Matasar, Alison J Mo...> ;Cancers. 2023 Mar 14
• Correction: Moving towards biologically informed treatment strategies for T-cell lymphomas.
  Robert Stuver, Natasha Lewis, Ahmet Dogan, Steven M Horwitz> ;International Journal of Hematology. 2023 Apr 1
• 12 citations
  Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
  Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, Lubomir Sokol, Zhengming Chen, Nikita Kotlov, Grigorii Nos, Maria Sorokina, Vladislav Maksimov, Andrea Sboner, Michael Sig...> ;Blood. 2023 May 4
• 1 citations
  Moving towards biologically informed treatment strategies for T-cell lymphomas.
  Robert Stuver, Natasha Lewis, Ahmet Dogan, Steven M Horwitz> ;International Journal of Hematology. 2023 Apr 1
• The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma.
  Lilly Gu, Yuna Oh, Mary P Smith, Nicholas R Kurtansky, Steven Horwitz, Niloufer Kahn, Alison Moskowitz, Sarah J Noor, Patricia Myskowski, Veronica Rotemberg> ;Leukemia & Lymphoma. 2022 Dec 1
• Join now to see all

Journal Articles

• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
  Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
• TCR‐Δ Expression and Γδ+ T‐Cell Infiltrates in Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma and Other Cutaneous T‐Cell Lymphoproliferative Disorders  
  Patricia Myskowski, Melissa Pulitzer, Steven Horwitz, Meenal Kheterpal, Shamir Geller, Allison Moskowitz, Histopathology

Abstracts/Posters

• Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all